At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 35 enrolled
Drug / intervention
mouse gp100 plasmid DNA vaccine +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Injection of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Mouse gp100 DNA: A Pilot Study to Compare Intramuscular Jet Injection With Particle Mediated Delivery
In Brief
A Phase 1 clinical trial evaluating mouse gp100 plasmid DNA vaccine, The Dermal PowderMed® devices, and 1 other intervention for Intraocular Melanoma and Melanoma (Skin). Completed, enrolled 35 participants across 1 site.
Detailed Summary
RATIONALE: Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Giving the vaccine in different ways may make a stronger immune response and kill more tumor cells. PURPOSE: This randomized clinical trial is studying two different ways of giving vaccine therapy to compare how well they work in treating patients with stage IIB, stage IIC, stage III, or stage IV melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntraocular Melanoma, Melanoma (Skin)
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedNov 2006
Primary CompletionMar 2011
TodayJul 2026
First PostedNov 10, 2006
Enrollment StartOct 1, 2006
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 19.6 years ago
Interventions
mouse gp100 plasmid DNA vaccinebiological
The Dermal PowderMed® devicesdevice
intramuscularly (IM injection)other